A surge in kratom-related poisonings across the United States has prompted fresh scrutiny of the botanical market, but researchers warn that cracking down on the substance entirely could backfire on patients who depend on it.
The CDC documented a dramatic rise in poisoning cases tied to kratom over the past decade, with cases jumping notably in 2025. Pharmacology experts attribute much of the spike to synthetic variants rather than natural kratom itself.
Walter Prozialeck, a pharmacology professor at Midwestern University, noted that the poisoning trend aligns with what many researchers expected. He pointed to synthetic derivatives like 7-OH as the likely culprit driving hospitalizations and adverse reactions.
The distinction matters significantly for policy makers considering regulations. A blanket ban on kratom could harm vulnerable populations who use the plant to manage chronic pain or overcome addiction, according to expert opinion. Many patients lack safer alternatives and rely on kratom's potential therapeutic properties.
Natural kratom, derived from the leaves of a Southeast Asian tree, has been used traditionally for decades. Researchers emphasize that unmodified versions differ fundamentally from lab-created synthetic knockoffs that can concentrate or alter alkaloid content unpredictably.
The challenge facing regulators involves distinguishing between genuinely problematic synthetic products and naturally sourced kratom. Experts argue that targeted enforcement against counterfeit or chemically altered versions would address the poisoning surge more effectively than sweeping prohibitions that could eliminate access for people managing legitimate health conditions.
Comments